Flunisolide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317885

CAS#: 3385-03-3

Description: Flunisolide is a corticosteroid often prescribed as treatment for allergic rhinitis. Intranasal corticosteroids are the most effective medication for controlling symptoms. The principal mechanism of action of flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.

Chemical Structure

img
Flunisolide
CAS# 3385-03-3
Instruction

Theoretical Analysis

MedKoo Cat#: 317885
Name: Flunisolide
CAS#: 3385-03-3
Chemical Formula: C24H31FO6
Exact Mass: 434.21
Molecular Weight: 434.498
Elemental Analysis: C, 66.34; H, 7.19; F, 4.37; O, 22.09

Price and Availability

Size Price Availability Quantity
50mg USD 285 2 Weeks
100mg USD 515 2 Weeks
Bulk inquiry

Synonym: Flunisolide, AeroBid, Nasalide, Nasarel, Bronalide, Synaclyn, Lunis

IUPAC/Chemical Name: (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one

InChi Key: XSFJVAJPIHIPKU-XWCQMRHXSA-N

InChi Code: InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1

SMILES Code: O=C1C=C[C@]2(C)[C@@]3([H])[C@@H](O)C[C@]4(C)[C@]5(C(CO)=O)OC(C)(C)O[C@]5([H])C[C@@]4([H])[C@]3([H])C[C@H](F)C2=C1

Appearance: White to off-white crystalline powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 434.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Flunisolide. 2023 Apr 15. PMID: 29999758.


2: Melani AS. Flunisolide for the treatment of asthma. Expert Rev Clin Pharmacol. 2014 May;7(3):251-8. doi: 10.1586/17512433.2014.908117. Epub 2014 Apr 9. PMID: 24716719.


3: Berger WE, Tashkin DP. Flunisolide hydrofluoroalkane with integrated spacer for treating asthma: an updated review. Allergy Asthma Proc. 2015 Mar- Apr;36(2):105-15. doi: 10.2500/aap.2015.36.3835. Epub 2015 Jan 29. PMID: 25635610.


4: Waugh J, Goa KL. Flunisolide HFA. Am J Respir Med. 2002;1(5):369-72; discussion 373. doi: 10.1007/BF03256630. PMID: 14720039.


5: Corren J, Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther. 2003 Mar;25(3):776-98. doi: 10.1016/s0149-2918(03)80108-x. PMID: 12852702.


6: Drugs for allergic rhinitis and allergic conjunctivitis. Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64. PMID: 33848281.


7: Nolting A, Sista S, Abramowitz W. Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos. 2001 Dec;22(9):373-82. doi: 10.1002/bdd.274. PMID: 11870676.


8: Ferreira TPT, Lima JGME, Farias-Filho FA, Jannini de Sá YAP, de Arantes ACS, Guimarães FV, Carvalho VF, Hogaboam C, Wallace J, Martins MA, Silva PMRE. Intranasal Flunisolide Suppresses Pathological Alterations Caused by Silica Particles in the Lungs of Mice. Front Endocrinol (Lausanne). 2020 Jun 17;11:388. doi: 10.3389/fendo.2020.00388. PMID: 32625168; PMCID: PMC7311565.


9: Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011993. doi: 10.1002/14651858.CD011993.pub2. PMID: 27115215; PMCID: PMC8939045.


10: Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated. Expert Opin Pharmacother. 2004 May;5(5):1163-73. doi: 10.1517/14656566.5.5.1163. PMID: 15155115.


11: Nolting A, Sista S, Abramowitz W. Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharm Sci. 2002 Feb;91(2):424-32. doi: 10.1002/jps.10030. PMID: 11835202.


12: Kantar A. What makes flunisolide different among inhaled corticosteroids used for nebulization: a close look at the role of aqueous solubility. Multidiscip Respir Med. 2021 Jan 15;16(1):719. doi: 10.4081/mrm.2021.719. PMID: 33489120; PMCID: PMC7816085.


13: Kantar A, Mroueh S, Fiocchi A. A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. Allergy Asthma Proc. 2007 Nov-Dec;28(6):671-87. doi: 10.2500/aap.2007.28.2979. PMID: 17883883.


14: Chaplin MD, Rooks W 2nd, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther. 1980 Mar;27(3):402-13. doi: 10.1038/clpt.1980.54. PMID: 7357797.


15: Richards J, Hirst P, Pitcairn G, Mahashabde S, Abramowitz W, Nolting A, Newman SP. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med. 2001 Summer;14(2):197-208. doi: 10.1089/08942680152484126. PMID: 11681651.


16: Baldino L, Scognamiglio M, Reverchon E. Supercritical CO2 Extraction of Organic Solvents from Flunisolide and Fluticasone Propionate. Pharmaceutics. 2021 Apr 23;13(5):612. doi: 10.3390/pharmaceutics13050612. PMID: 33922659; PMCID: PMC8146547.


17: Brenner BE, Chavda KK, Camargo CA Jr. Randomized trial of inhaled flunisolide versus placebo among asthmatic patients discharged from the emergency department. Ann Emerg Med. 2000 Nov;36(5):417-26. doi: 10.1067/mem.2000.110824. PMID: 11054193.


18: Varricchio A, Capasso M, De Lucia A, Avvisati F, Varricchio AM, Bettoncelli G, Ciprandi G. Intranasal flunisolide treatment in patients with non-allergic rhinitis. Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):401-9. doi: 10.1177/039463201102400213. PMID: 21658314.


19: Silvers WS, Cohen R, D'Alonzo G, Fishken D, Lim JC, Stokes AL, McNally CF. Comparative taste evaluation of aerosolized formulations of triamcinolone acetonide, flunisolide, and flunisolide with menthol. Clin Ther. 1993 Nov- Dec;15(6):988-93. PMID: 8111818.


20: Dickens GR, Wermeling DP, Matheny CJ, John W, Abramowitz W, Sista SM, Foster T, Choudhury S. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol. 2000 May;84(5):528-32. doi: 10.1016/S1081-1206(10)62517-3. PMID: 10831007.